Hi Malmanu – a very good review of asthma apps and devices in general came out in BMC Medicine late last year.
www.biomedcentral.com/1741-7015/10/144
Your kind of right about GPs. But a lot of paediatric asthma is managed in tertiary settings.
Anyway for exactly the problem you are raising – the strategy is two fold.
Get the device approved OTC and second to get managed care (insurance in the US) to pay for the device. The old company tried for years to achieve this and never did.
So far ISN have failed at the first and not started on the second.
The fundamentals make no sense. Its a waste of time arguing for or against them.
The key questions here are to whether to pay off the mortgage, where to have a holiday overseas and how to incorporate capital gains tax considerations into ones trading approach.
All interesting questions but of very little practical significance to me (sadly).
Cheers Southoz
ISN Price at posting:
66.5¢ Sentiment: None Disclosure: Not Held
